Northern Trust Corp Has $25.93 Million Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Northern Trust Corp lifted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 18.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 717,161 shares of the specialty pharmaceutical company's stock after purchasing an additional 110,867 shares during the quarter. Northern Trust Corp owned 1.30% of Supernus Pharmaceuticals worth $25,933,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Barclays PLC grew its stake in Supernus Pharmaceuticals by 88.3% during the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company's stock worth $3,393,000 after buying an additional 51,005 shares in the last quarter. Franklin Resources Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 7.6% during the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company's stock worth $987,000 after acquiring an additional 2,121 shares during the period. Empowered Funds LLC acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $1,498,000. Smartleaf Asset Management LLC increased its stake in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after acquiring an additional 870 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Supernus Pharmaceuticals by 40.6% in the third quarter. JPMorgan Chase & Co. now owns 253,396 shares of the specialty pharmaceutical company's stock valued at $7,901,000 after acquiring an additional 73,118 shares during the last quarter.

Supernus Pharmaceuticals Trading Down 2.3%

NASDAQ:SUPN traded down $0.74 during trading hours on Wednesday, hitting $31.54. 423,213 shares of the company were exchanged, compared to its average volume of 492,906. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of 29.48 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a one year low of $25.53 and a one year high of $40.28. The company has a fifty day simple moving average of $31.87 and a 200 day simple moving average of $34.87.

Analyst Upgrades and Downgrades

SUPN has been the topic of a number of research analyst reports. StockNews.com downgraded Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 8th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Insider Buying and Selling

In other news, SVP Jonathan Rubin sold 927 shares of the business's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the transaction, the senior vice president now owns 7,853 shares in the company, valued at approximately $307,444.95. The trade was a 10.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 9.30% of the stock is owned by insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.